phenytoin has been researched along with sorafenib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Al-Ach, NN; Al-Tel, TH; Alshihabi, AM; Anbar, HS; El-Awady, R; El-Gamal, MI; El-Gamal, R; Kalla, RR; Munther, MA; Sbenati, RM; Shahin, AI; Shehata, MK; Tarazi, H; Tokatly, RT; Wahba, MM; Zaraei, SO | 1 |
| Shi, K; Wang, J; Wang, Y; Zhang, J; Zhou, E | 1 |
2 review(s) available for phenytoin and sorafenib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities.
Topics: Apoptosis; Chemistry, Pharmaceutical; Drug Discovery; Humans; Receptor-Interacting Protein Serine-Threonine Kinases | 2022 |
1 other study(ies) available for phenytoin and sorafenib
| Article | Year |
|---|---|
Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity.
Topics: Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Hydroxyquinolines; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Quinolines; Sorafenib; Structure-Activity Relationship | 2022 |